Uvax Bio
Ke Li is currently serving as the Vice President of Vaccine Development and Technical Ops at Uvax Bio. With a Ph.D. in Organic Chemistry from New York University, Ke has extensive experience in the pharmaceutical industry, holding roles such as Director at Wilmington PharmaTech Company LLC and Associate Director at Zymergen. Prior to these positions, Ke worked as a Senior Research Investigator at DuPont and as a Research Associate at The Scripps Research Institute. Ke holds an MBA from the University of Delaware and a B.S. in Chemistry from Jilin University.
This person is not in any offices
Uvax Bio
Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.